139 related articles for article (PubMed ID: 36726902)
21. Ectomesenchymal Chondromyxoid Tumour of the Dorsal Tongue Presenting with Impaired Speech.
Schep LA; Bullock MJ; Taylor SM
Case Rep Otolaryngol; 2016; 2016():7342910. PubMed ID: 27239359
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
[TBL] [Abstract][Full Text] [Related]
23. Ectomesenchymal chondromyxoid tumor: Review of literature and a report of a rare case.
Leeky M; Narayan T; Shenoy S; Jamadar S
J Oral Maxillofac Pathol; 2011 Jan; 15(1):74-9. PubMed ID: 21731283
[TBL] [Abstract][Full Text] [Related]
24. Ectomesenchymal chondromyxoid tumor of the anterior aspect of the tongue.
Seckin D; Demirkesen C; Gurbuz O
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S23-4. PubMed ID: 18625372
[TBL] [Abstract][Full Text] [Related]
25. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
[TBL] [Abstract][Full Text] [Related]
26. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
27. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
28. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
29. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
30. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
[TBL] [Abstract][Full Text] [Related]
31. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
32. [Ectomesenchymal chondromyxoid tumor of the anterior tongue].
Muenst S; Jakscha J; Jundt G; Glatz K
Pathologe; 2011 Nov; 32(6):517-20. PubMed ID: 21681469
[TBL] [Abstract][Full Text] [Related]
33. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
[TBL] [Abstract][Full Text] [Related]
34. A case of a CD56-expressing ectomesenchymal chondromyxoid tumor of the tongue: potential diagnostic usefulness of commonly available CD56 over CD57.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(3):3328-33. PubMed ID: 26045862
[TBL] [Abstract][Full Text] [Related]
35. Is fetal cellular rhabdomyoma an entity or a differentiated rhabdomyosarcoma? A study of patients with rhabdomyoma of the tongue and sarcoma of the tongue enrolled in the intergroup rhabdomyosarcoma studies I, II, and III.
Kodet R; Fajstavr J; Kabelka Z; Koutecky J; Eckschlager T; Newton WA
Cancer; 1991 Jun; 67(11):2907-13. PubMed ID: 2025857
[TBL] [Abstract][Full Text] [Related]
36. PAX3-NCOA1 alveolar rhabdomyosarcoma of the tongue: A rare entity with challenging diagnosis and management.
Di Carlo D; Chargari C; Scoazec JY; Cotteret S; Felix A; Moalla S; Temam S; Minard-Colin V
Pediatr Blood Cancer; 2021 Nov; 68(11):e29288. PubMed ID: 34424607
[TBL] [Abstract][Full Text] [Related]
37. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
[TBL] [Abstract][Full Text] [Related]
38. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM
Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
[TBL] [Abstract][Full Text] [Related]
39. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
40. Ectomesenchymal chondromyxoid tumor in the anterior tongue: case report of a unique tumor.
Pak MG; Kim KB; Shin N; Kim WK; Shin DH; Choi KU; Sol MY
Korean J Pathol; 2012 Apr; 46(2):192-6. PubMed ID: 23110000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
